© 1996 American Heart Association, Inc.
Articles |
Apolipoprotein E Alleles and Risk of Coronary Disease
A Meta-analysis
the Framingham Heart Study, National Heart, Lung, and Blood Institute (P.W.F.W.) and Boston University (M.G.L.), Framingham, and Tufts USDA Nutrition Center, Boston (E.J.S., J.M.O.), Mass.
Correspondence to Peter W.F. Wilson, MD, Framingham Heart Study, National Heart, Lung, and Blood Institute, 5 Thurber St, Framingham, MA 01701. E-mail peter@fram.nhlbi.nih.gov.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
A meta-analysis was undertaken to assess the impact of apolipoprotein E (apo E) alleles (
2, 3, and 4) on coronary disease in 14 published observational studies (9 clinical coronary disease and 5 coronary angiography). In comparison with 3, the 4 allele was associated with greater odds for coronary heart disease, and summary estimates of the odds ratios (ORs) and (95% confidence intervals) for both sexes combined were OR=0.98 (0.85-1.14) for 2 and OR=1.26 (1.13-1.41) for 4. Separate analyses for men and women showed similar associations. In angiographic studies the relative odds for significant coronary artery disease among both sexes combined was OR=0.76 (0.55-1.05) for 2 and OR=1.11 (0.88-1.40) for 4. The overall impression is that 4 is associated with clinical and coronary disease and that results are similar in men and women.
Key Words: apolipoprotein E • coronary heart disease • meta-analysis • molecular epidemiology
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
First described in the 1970s, six common isoforms of apo E typically occur in plasma. They are denoted apo E 2/2, 2/3, 3/3, 3/4, 2/4, and 4/4 and are encoded by the
2, 3, and 4 alleles on human chromosome 19.1 2 The 3 allele is the most common, and 
60% of North Americans are homozygous for this genetic variant. The 2 and 4 alleles are distinguished by single amino acid substitutions at residues 112 and 158, respectively, of the 299–amino acid chain that constitutes mature apo E. Although early interest in the apo E isoforms was focused on the description of genetic defects associated with severely abnormal lipid levels,3 4 recent literature has emphasized the effects of these mutations on the normal variation of lipid levels in the general population and the impact of these alleles on CHD.5 6 7 8 The present article provides an overview of the literature concerning apo E alleles and coronary disease in middle-aged adults. Although this review draws on one prospective study of CHD death,9 the project draws largely from case-control and cross-sectional studies that have examined the prevalence of CHD according to apo E phenotype. Because most investigators who examined the relation between apo E alleles and CHD reported apo E phenotype data for both case and control subjects, it is possible with meta-analytic techniques to make an overall estimate of the association between apo E alleles and CHD from these studies.
Specific topics to be considered include whether certain isoforms or alleles, particularly 4, are associated with an increased prevalence of CAD; the consistency of reported results; and the degree to which sex, age, or geographic location might exert an effect. In addition to reviewing the data for clinical CHD, published information that relates apo E isoforms to arteriographic CAD is considered.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Medical reports based on clinical observational studies published in English after 1978, when apo E isoforms were first described, were considered for this review. Candidate articles were located by MEDLINE and manual search methods using the key words apolipoproteins, coronary heart disease, and coronary artery disease. Plasma methods, mostly isoelectric focusing, were largely used to determine apo E phenotypes for the studies considered in this review.10 The frequency of apo E phenotypes was estimated from apo E allele data where necessary.9
Only clinical studies involving adults, typically within the 40- to 70-year age span, were considered. The Premature Development of Atherosclerosis in Youth (PDAY), a large autopsy database of aortic and coronary atherosclerosis in adults 18 to 34 years, was excluded because it was not a clinical study, postmortem information was the basis for inclusion in that investigation, and subjects were younger.11 A study of premature atherosclerosis in European subjects 18 to 26 years old was also excluded because of age and the fact that the clinical context of the study was disease in parents of the participants, not the participants themselves.12
Most investigators used a case-control design,13 14 15 16 but the Framingham and European Etude Cas Temoin Infarctus du Myocarde (ECTIM) investigations were derived from community samples,6 7 and Eichner et al17 used a nested case-control approach for participants in the Multiple Risk Factor Intervention Trial (MRFIT). In the latter project, apo E phenotyping of previously frozen plasma was used for men who developed CHD and for a group of age-matched, CHD-free control subjects.5 Although most studies focused on CHD morbidity, a prospective investigation of CHD death in Finnish men 65 to 84 years old was also included.9 The Finnish investigators performed separate analyses for eastern and southwestern samples, denoted StengardE and StengardSW, respectively, and this report was considered as two separate studies for the purpose of this meta-analysis.
Reports with a full description of selection criteria were considered, and it was also required that each study reported apo E isoform information for cases and a suitable comparison group. The coronary events included MI, angina pectoris, or death from coronary disease, but it was not possible to validate diagnostic criteria across studies. For instance, in the population-based studies, MRFIT cases included nonfatal MI and CAD death, ECTIM cases were MI survivors who met the criteria of a World Health Organization surveillance program, the Framingham Study cases were subjects with a previous MI or angina pectoris, and the Finnish study of elderly men used CHD death as the end point. Separate analyses were conducted for arteriographic studies,18 19 20 21 22 in which apo E phenotypes were determined at the time of cardiac catheterization for evaluation of chest discomfort.
Comparison groups in most investigations were of the same sex as cases, but in two Japanese reports15 16 and one other investigation,13 the sex of the control subjects was not specified and their apo E phenotype frequencies were used in comparisons for men and women. Data for rare alleles such as 1 and 5 (total, <1% of the worldwide population5 15 16 ) were given in some reports but excluded in this analysis.
Summary estimates for the associations between apo E alleles and CHD were calculated for men, women, and overall. Statistical methods included use of single-gene models and 
2 methods to estimate the effect of 2 and 4 alleles on the relative odds of clinical CHD and arteriographic CAD for individual studies.7 23 By this method the proportion of cases and control subjects with the 4 allele (apo E 2/4, 3/4, or 4/4) was compared with the number of persons homozygous for 3 (apo E 3/3). Case and control subjects were also compared for the presence of 2 (apo E 2/4, 2/3, or 2/2) relative to 3 homozygotes. Summary estimates of the association of apo E alleles with CHD and CAD were made with the Mantel-Haenszel modification of a fixed-effects meta-analysis model24 25 26 by combining studies within each sex and then across sexes. Similar results (not shown) were obtained with the Peto modification of a fixed-effects model.24 Tests for heterogeneity were performed with the Breslow-Day technique.27
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The relative frequencies of apo E phenotypes among CHD cases and comparison groups appear in Tables 1 and 2
for men and women, respectively. The percentage of cases with the apo E 4/4 phenotype equals or exceeds the proportion of control subjects with apo E 4/4 for all reports among men. Similarly, the apo E 3/4 phenotype is more common among cases than control subjects in almost all studies of CHD in men (Table 1). The tendency toward a higher proportion of apo E 4/4 and 3/4 phenotypes in cases than control subjects also occurs in women (Table 2). No striking differences in the frequency of apo E 2/2 or 2/3 among case and control subjects were observed for either sex.
|
|
In Table 3 the presence of arteriographic CAD in case and control subjects is compared across five studies. In most instances the frequency of apo E 4/4 but not necessarily apo E 3/4 is greater among cases. The opposite pattern is observed for apo E 2/3, and the latter phenotype tends to be less common among cases compared with control subjects.
|
Allele frequencies of 2 and 4 were calculated for each study in Tables 1 and 2
, and the relative odds for CHD with respect to the 3 allele were determined by single-gene models. These results for men, women, and both sexes combined appear in Table 4. Because the study of Utermann et al28 did not specify the sex of either cases or control subjects, relative odds for CHD were estimated for both sexes combined. Several investigations did not include women, and the same relative odds estimate for CHD is shown in the columns for men and for both sexes combined. Each entry represents the OR, an estimate of the relative odds for CHD associated with a specific allele compared with that for the 3 allele. At the foot of each column is a summary odds ratio. This last estimate is weighted by the variance of the contributing studies. For instance, for 4 the OR and (95% CI) of the estimate associated with CHD in both sexes combined is 1.26 (1.13-1.41).
|
Tests for heterogeneity (9 studies of men, 4 of women, and 1 of both sexes) show for 4: Qheterogeneity=33.6 (13 df), P=.001. The study of Utermann et al,28 in which a tendency toward cardioprotection was observed for 4, produced a result different from that in other investigations and is responsible for more than half of the heterogeneity. Without those data the results for 4 are as follows: OR=1.44 (1.27-1.62), Qheterogeneity=13.8 (12 df), P=.32. Similarly, a heterogeneity test for 2 including all studies in Table 4 yields the following: Qheterogeneity=28.1 (13 df), P=.009. No single study appeared to account for the variation in the overall 2 estimate. The report by Eto et al15 accounted for more than one third of the heterogeneity, but removal of that study from analysis did not substantially alter the overall OR estimate, and the overall impression is that 2 is not associated with CHD. The 4 associations with CHD for both sexes combined are shown for each study in the Figure. At the bottom of the Figure are shown two summary estimates of the relative odds of CHD associated with 4: the first, with the study of Utermann et al, and the second without it.
|
Table 5 follows the same format as that for Table 4, except that arteriographic CAD is considered for both sexes combined. The overall relative odds for CAD associated with 4 is OR=1.11 (0.88-1.40). The test of heterogeneity for 4 associated with Table 5 yields the following: Qheterogeneity=14.5 (4 df), P=.006. The data for arteriographic CAD do not support a relation with either 2 or 4.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Summary estimates for the association of
2 and 4 alleles with clinical CHD are based on 9 reports (a total of 10 studies, as one Finnish report is considered to be two separate studies) that included 1971 male (Table 1) and 181 female (Table 2) cases compared with a similar number of suitable control subjects. Summary estimates indicated that the relative odds for CHD among persons with the 2 allele were 0.98 (0.85-1.14) for both sexes combined. Similar results for 2 were obtained when the data for each sex were analyzed separately. Because the relative odds are close to 1.00 and the (95% CI) of the estimate includes 1.00, the data suggest that the relative odds for CHD are neither higher nor lower among persons with the 2 allele.
Information for the 4 allele suggests an association with higher relative odds for CHD among men, women, and both sexes combined (Table 4 and the Figure). The relative odds of 1.38 (1.22-1.57) for men indicate that the odds associated with the 4 allele (apo E 2/4, 3/4, or 4/4) are 38% higher than in apo E 3/3 men. Significant heterogeneity for the estimates in Table 4 is evidence for disparity between studies. For instance, for the association of the 4 allele with CHD for both sexes combined, the study of Utermann et al28 suggests a decrease; the studies of Cumming and Robertson,13 Lenzen et al,14 and Yamamura et al16 show a nonsignificant increase; and the reports of Luc et al,6 Wilson et al,7 Stengard et al9 (southwestern region), Eto et al,15 and Eichner et al17 show a significant increase. Significant heterogeneity in the 4 estimate for both sexes combined is largely attributed to the study by Utermann et al, an early report that did not identify the sex of cases or control subjects. When those data are included, however, the 4 effect is significant; with that study removed, the 4 effect is stronger and more significant.
Supporting data for a significant association between 4 and CHD are found in a report of European subjects 18 to 26 years of age that compared 635 persons with a paternal history of MI and 1259 subjects without such a history. Tiret et al12 showed that the 4 allele frequency was 1.25 times more common among subjects whose fathers had sustained an MI.
Although fewer arteriographic studies have been published, they tend to support the clinical data and complement the autopsy information from the PDAY study, in which the 4 allele was found to be associated with a greater degree of atherosclerosis among young adults who died traumatically.11 A recent case series of middle-aged Australian men and women lacked a control group but also demonstrated that persons with greater arteriosclerosis (ie, more vessels with clinically significant stenoses) at the time of cardiac catheterization were more likely to have the 4 allele and less likely to have 2.29
The actual mechanism by which the 4 allele might increase coronary artery risk has not been entirely worked out. Although apo E has been associated with dementia of the Alzheimer type and may act as a "chaperone" to promote ß-amyloid fibril formation in the brain,30 the pathobiology of coronary lesions has largely been linked to alterations in lipid metabolism.1 Transgenic mice with an apo E deficiency tend to develop high levels of lipoprotein remnants, cutaneous foam cells, and arterial lesions.31 32 On the other hand, murine strains with overexpressed apo E show increased clearance of apo B–containing particles and reduced levels of plasma cholesterol and triglycerides.33 34 Extrapolation of findings from these animal models to humans is difficult.35 Clinical studies have shown that apo E levels tend to be highest in those with the 2 allele, intermediate in those with 3, and lowest in those with 4,20 36 37 but apo E concentrations among CHD cases have been reported to be higher,38 lower,39 or no different40 41 from those in control subjects. Compared with 3, the 4 allele is associated with increased production and decreased peripheral catabolism of LDL particles.1 The opposite tendency is observed for 2: fewer LDL particles are produced, LDL catabolism is enhanced, and LDL cholesterol levels are typically reduced. The 2 allele may not be entirely benign, as it has been linked to a propensity for hypertriglyceridemia in several investigations and a meta-analysis.7 This tendency toward higher triglyceride levels may help explain why persons with the 2 allele do not typically experience protection from clinical CHD (Table 4) or arteriographic CAD (Table 5).
Estrogen status and the apo E alleles may jointly affect lipid levels. An increase in LDL cholesterol levels at menopause may be modulated by apo E status and may be more common in women with the 4 allele.42 The ECTIM study and Finnish reports have suggested that geography may play a role.1 6 Women living in regions farther from the equator, where the prevalence of 4 is relatively greater, a higher fat intake traditional, and population cholesterol and triglyceride levels higher, may be particularly susceptible to an apo E gene–environment interaction that promotes CHD.
The population-attributable risk for 4 has been estimated in two population-based studies at 12% and 15%.6 7 Because these estimates depend on the prevalence of the 4 allele in the study sample, it is not appropriate to make such estimates in case-control studies. This attributable-risk percent is interpreted as the fraction of CHD that can be attributed to the presence of the 4 allele and suggests that this genetic marker exerts an important influence on CHD development in Western populations. The corresponding attributable-risk percent for MI associated with familial hypercholesterolemia is 5%7 and suggests that apo E markers are important clinical phenotypes in the causation of clinical atherosclerosis. The final impression is that the 4 allele is associated with a greater relative risk for vascular disease of the heart and that these results are similar in men and women. The role of the 2 allele in CHD is less certain. Although the 2 allele is associated with lower LDL cholesterol concentrations, this does not necessarily imply that 2 is cardioprotective because of its tendency to be associated with hypertriglyceridemia.
|
Selected Abbreviations and Acronyms |
|---|
|
Received February 15, 1996; accepted March 20, 1996.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1-21.
2. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. In: Born GVR, Schwartz CJ, eds. New Horizons in Coronary Heart Disease. London, England: Current Science; 1993:5.1-5.21.
3. Utermann G, Vogelberg KH, Steinmetz A, Schoenborn W, Pruin N, Jaeschke M, Hees M, Canzler H. Polymorphism of apolipoprotein E, II: genetics of hyperlipoproteinemia type III. Clin Genet. 1979;15:37-62.[Medline] [Order article via Infotrieve]
4. Utermann G, Pruin N, Steinmetz A. Polymorphism of apolipoprotein E, III: effect of a single polymorphic gene locus on plasma lipid levels in man. Clin Genet. 1979;15:63-72.[Medline] [Order article via Infotrieve]
5. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, Neaton JD. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. 1993;71:160-165.[Medline] [Order article via Infotrieve]
6.
Luc G, Bard J, Arveiler D, Evans A, Cambou J, Bingham A, Amouyel P, Schaffer P, Ruidavets J, Cambien F, Fruchart J, Ducimetiere P. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction: the ECTIM Study. Arterioscler Thromb. 1994;14:1412-1419.
7.
Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham Offspring Study. JAMA. 1994;272:1666-1671.
8.
Dammerman M, Breslow JL. Genetic basis of lipoprotein disorders. Circulation. 1995;91:505-512.
9.
Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation. 1995;91:265-269.
10. Ordovas JM, Litwack-Klein L, Wilson PWF, Schaefer EJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of Apo E1 and Apo E5 isoforms in the Framingham Offspring Study. J Lipid Res. 1987;28:371-380.[Abstract]
11.
Hixson JE, PDAY Research Group. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Arterioscler Thromb. 1991;11:1237-1244.
12.
Tiret L, de Knijff P, Menzel H, Ehnholm C, Nicaud V, Havekes LM. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations: the EARS Study. Arterioscler Thromb. 1994;14:1617-1624.
13. Cumming AM, Robertson F. Polymorphism at the apo E locus in relation to risk of coronary disease. Clin Genet. 1984;25:310-313.[Medline] [Order article via Infotrieve]
14.
Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem. 1986;32:778-781.
15. Eto M, Watanabe K, Makino I. Increased frequencies of apolipoprotein e2 and e4 alleles in patients with ischemic heart disease. Clin Genet. 1989;36:183-188.[Medline] [Order article via Infotrieve]
16. Yamamura T, Tajima S, Miyake Y, Nomura S, Yamamoto A, Haze K, Hiramori K. Hyperlipoproteinemia as a risk factor for ischemic heart disease. Jpn Circ J. 1990;54:448-456.[Medline] [Order article via Infotrieve]
17.
Eichner JE, Kuller LH, Ferrell RE, Meilahn EN, Kamboh MI. Phenotypic effects of apolipoprotein structural variation on lipid profiles, I: contribution of apolipoprotein E phenotype to prediction of total cholesterol, apolipoprotein B, and low density lipoprotein cholesterol in the Healthy Women Study. Arteriosclerosis. 1990;10:379-385.
18.
Menzel H, Kladetzky R, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis. 1983;3:310-315.
19.
Kuusi T, Nieminen MS, Ehnholm C, Yki-Karvinen H, Valle M, Nikkila EA, Taskinen M. Apoprotein E polymorphism and coronary artery disease: increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis. 1989;9:237-241.
20. Stuyt PMJ, Brenninkmeijer BJ, Damacker PNM, Hendriks JCM, van Elteren P, Stalenhoef AFH, van't Laar A. Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease. Scand J Clin Lab Invest. 1991;51:425-435.[Medline] [Order article via Infotrieve]
21. van Bockxmeer FM, Mamotte CD. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet. 1992;340:879-880.[Medline] [Order article via Infotrieve]
22. Lehtinen S, Lehtimaki T, Sisto T, Salenius JP, Nikkila M, Jokela H, Koivula T, Ebeling F, Ehnholm C. Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis. 1995;114:83-91.[Medline] [Order article via Infotrieve]
23. Boerwinkle E, Visvikis S, Welsh D, Steinmetz J, Hanash SM, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man, II: the role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am J Med Genet. 1987;27:567-582.[Medline] [Order article via Infotrieve]
24. Petitti DB. Statistical methods in meta-analysis. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York, NY: Oxford; 1994:90-114.
25. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141-151.[Medline] [Order article via Infotrieve]
26. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials. 1994;7:177-188.
27. Breslow NE, Day NE. Classical methods of S analysis of matched data. In: Davis W, ed. Statistical Methods in Cancer Research: The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980:162-189.
28. Utermann G, Hardewig A, Zimmer F. Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet. 1984;65:237-241.[Medline] [Order article via Infotrieve]
29.
Wang XL, McCredie RM, Wilcken DEL. Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol. 1995;15:1030-1034.
30. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J. 1995;306:599-604.
31. Feingold KR, Elias PM, Mao-Qiang M, Fartasch M, Zhang SH, Maeda N. Apolipoprotein E deficiency leads to cutaneous foam cell formation in mice. J Invest Dermatol. 1995;104:246-250.[Medline] [Order article via Infotrieve]
32.
Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
33. Shimano H, Yamada N, Katsuki M, Yamamoto K, Gotoda T, Harada K, Shimada M, Yazaki Y. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E: accelerated clearance of lipoproteins containing apolipoprotein B. J Clin Invest. 1992;90:2084-2091.
34.
Yamada N, Shimano H, Mokuno H, Ishibashi S, Gotohda T, Kawakami M, Watanabe Y, Akanuma Y, Murase T, Takaku F. Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hyperlipidemic rabbits. Proc Natl Acad Sci U S A. 1989;86:665-669.
35. Rader DJ, Wilson JM. Gene therapy for lipid disorders. In: Haber E, ed. Molecular Cardiovascular Medicine. New York, NY: Scientific American; 1995:97-114.
36. Boerwinkle E, Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet. 1988;42:104-122.[Medline] [Order article via Infotrieve]
37. Reilly SL, Ferrell RE, Kottke BA, Kamboh MI, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN, I: pleiotropic effects on means and variances. Am J Hum Genet. 1991;49:1155-1166.[Medline] [Order article via Infotrieve]
38. Chivot L, Mainard F, Bigot E, Bard JM, Auget JL, Madec Y, Fruchart JC. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. Arteriosclerosis. 1990;82:205-211.
39.
Couderc R, Mahieux F, Bailleul S, Fenelon G, Mary R, Fernamian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: a case-control study. Stroke. 1993;24:661-664.
40.
Buring JE, O'Connor GT, Goldhaber SZ, Rosner B, Herbert PN, Blum CB, Breslow JL, Hennekens CH. Decreased HDL2 and HDL3 cholesterol, apo A-I and apo A-II, and increased risk of myocardial infarction. Circulation. 1992;85:22-29.
41. Bittolo Bon G, Cazzolato G, Saccardi M, Kostner GM, Avogaro P. Total plasma apo E and high density lipoprotein E in survivors of myocardial infarction. Atherosclerosis. 1984;54:69-77.
42.
Schaefer EJ, Lamon-Fava S, Johnson S, Ordovas JM, Schaefer MM, Castelli WP, Wilson PWF. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels: results from the Framingham Offspring Study. Arterioscler Thromb. 1994;14:1105-1113.
This article has been cited by other articles:
 |
|
 |
|
  M. Belohlavek, P. Jiamsripong, A. M. Calleja, E. M. McMahon, C. L. Maarouf, T. A. Kokjohn, T. L. Chaffin, L. J. Vedders, Z. Garami, T. G. Beach, et al. Patients With Alzheimer Disease Have Altered Transmitral Flow: Echocardiographic Analysis of the Vortex Formation Time J. Ultrasound Med., November 1, 2009; 28(11): 1493 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ward, P. N. Mitrou, R. Bowman, R. Luben, N. J. Wareham, K.-T. Khaw, and S. Bingham APOE Genotype, Lipids, and Coronary Heart Disease Risk: A Prospective Population Study Arch Intern Med, August 10, 2009; 169(15): 1424 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kolovou, D. Damaskos, K. Anagnostopoulou, and D. V. Cokkinos Apolipoprotein E Gene Polymorphism and Gender Ann. Clin. Lab. Sci., January 1, 2009; 39(2): 120 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. KOLOVOU, K. K. ANAGNOSTOPOULOU, P. KOSTAKOU, V. GIANNAKOPOULOU, C. MIHAS, G. HATZIGEORGIOU, I. K. VASILIADIS, D. P. MIKHAILIDIS, and D. V. COKKINOS Apolipoprotein E Gene Polymorphism and Obesity Status in Middle-aged Men with Coronary Heart Disease In Vivo, January 1, 2009; 23(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Silbert, L. A. Evered, D. A. Scott, and T. F. Cowie The Apolipoprotein E {epsilon}4 Allele is not Associated With Cognitive Dysfunction in Cardiac Surgery Ann. Thorac. Surg., September 1, 2008; 86(3): 841 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. F. Wilson CETP Genes, Metabolic Effects, and Coronary Disease Risk JAMA, June 18, 2008; 299(23): 2795 - 2796. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Bennet, E. Di Angelantonio, Z. Ye, F. Wensley, A. Dahlin, A. Ahlbom, B. Keavney, R. Collins, B. Wiman, U. de Faire, et al. Association of Apolipoprotein E Genotypes With Lipid Levels and Coronary Risk JAMA, September 19, 2007; 298(11): 1300 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Reitz, T. den Heijer, C. van Duijn, A. Hofman, and M.M.B. Breteler Relation between smoking and risk of dementia and Alzheimer disease: The Rotterdam Study Neurology, September 4, 2007; 69(10): 998 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Chiodini, M. G. Franzosi, S. Barlera, S. Signorini, C. M. Lewis, A. D'Orazio, P. Mocarelli, E. Nicolis, R. Marchioli, G. Tognoni, et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study Eur. Heart J., August 2, 2007; 28(16): 1977 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Arnett, A. E. Baird, R. A. Barkley, C. T. Basson, E. Boerwinkle, S. K. Ganesh, D. M. Herrington, Y. Hong, C. Jaquish, D. A. McDermott, et al. Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, June 5, 2007; 115(22): 2878 - 2901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Morgan, H. M. Krumholz, R. P. Lifton, and J. A. Spertus Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study JAMA, April 11, 2007; 297(14): 1551 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Neville, R. Clarke, J. G. Evans, D. C. Rubinsztein, and F. Karpe Absence of Relationship Between MTTP Haplotypes and Longevity J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2007; 62(2): 202 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Tziakas, G. K. Chalikias, C. O. Antonoglou, S. Veletza, I. K. Tentes, A. X. Kortsaris, D. I. Hatseras, and J. C. Kaski Apolipoprotein E Genotype and Circulating Interleukin-10 Levels in Patients With Stable and Unstable Coronary Artery Disease J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2471 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Stakias, P. Liakos, E. Tsiapali, M. Goutou, and G. N. Koukoulis Lower Prevalence of Epsilon 4 Allele of Apolipoprotein E Gene in Healthy, Longer-Lived Individuals of Hellenic Origin J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2006; 61(12): 1228 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bursi, W. A. Rocca, J. M. Killian, S. A. Weston, D. S. Knopman, S. J. Jacobsen, and V. L. Roger Heart Disease and Dementia: A Population-based Study Am. J. Epidemiol., January 15, 2006; 163(2): 135 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Prepared by: British Cardiac Society, British Hype JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart, December 1, 2005; 91(suppl_5): v1 - v52. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Karra, S. Vemullapalli, C. Dong, E. E. Herderick, X. Song, K. Slosek, J. R. Nevins, M. West, P. J. Goldschmidt-Clermont, and D. Seo Molecular evidence for arterial repair in atherosclerosis PNAS, November 15, 2005; 102(46): 16789 - 16794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Kolovou, K. K. Anagnostopoulou, D. P. Mikhailidis, D. B. Panagiotakos, N. D. Pilatis, M. A. Cariolou, N. Yiannakouris, D. Degiannis, G. Stavridis, and D. V. Cokkinos Association of Apolipoprotein E Genotype with Early Onset of Coronary Heart Disease in Greek Men Angiology, November 1, 2005; 56(6): 663 - 670. [Abstract] [PDF]
|
|
|
|
|
|
G. D. Kolovou, K. K. Anagnostopoulou, K. D. Salpea, D. B. Panagiotakos, I. S. Hoursalas, M. A. Cariolou, K. Koniavitou, and D. V. Cokkinos Apolipoprotein E Genotype in Matched Men and Women with Coronary Heart Disease Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 391 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Patel Shared genetic risk factors for obstructive sleep apnea and obesity J Appl Physiol, October 1, 2005; 99(4): 1600 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. BEDNARSKA-MAKARUK, M. RODO, C. MARKUSZEWSKI, A. ROZENFELD, M. SWIDERSKA, B. HABRAT, and H. WEHR POLYMORPHISMS OF APOLIPOPROTEIN E AND ANGIOTENSIN-CONVERTING ENZYME GENES AND CAROTID ATHEROSCLEROSIS IN HEAVY DRINKERS Alcohol Alcohol., July 1, 2005; 40(4): 274 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hubacek, A. Horinek, Z. Skodova, V. Adamkova, R. Ceska, L. Zlatohlavek, and M. Vrablik Hypertriglyceridemia: Interaction between APOE and APOAV Variants Clin. Chem., July 1, 2005; 51(7): 1311 - 1313. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zareparsi, M. Buraczynska, K. E.H. Branham, S. Shah, D. Eng, M. Li, H. Pawar, B. M. Yashar, S. E. Moroi, P. R. Lichter, et al. Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration Hum. Mol. Genet., June 1, 2005; 14(11): 1449 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Paschos, N. Yiannakouris, L. S. Rallidis, I. Davies, B. A. Griffin, D. B. Panagiotakos, F. N. Skopouli, V. Votteas, and A. Zampelas Apolipoprotein E Genotype in Dyslipidemic Patients and Response of Blood Lipids and Inflammatory Markers to Alpha-Linolenic Acid Angiology, January 1, 2005; 56(1): 49 - 60. [Abstract] [PDF]
|
|
|
|
|
|
J. W. Stephens, M. M. Sozen, R. A. Whittall, M. J. Caslake, D. Bedford, J. Acharya, S. J. Hurel, and S. E. Humphries Three Novel Mutations in the Apolipoprotein E Gene in a Sample of Individuals with Type 2 Diabetes Mellitus Clin. Chem., January 1, 2005; 51(1): 119 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Djousse, J. S Pankow, D. K Arnett, J. H Eckfeldt, R. H Myers, and R C. Ellison Apolipoprotein E polymorphism modifies the alcohol-HDL association observed in the National Heart, Lung, and Blood Institute Family Heart Study Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1639 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Elosua, J. M. Ordovas, L. A. Cupples, C. S. Fox, J. F. Polak, P. A. Wolf, R. A. D'Agostino Sr., and C. J. O'Donnell Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study J. Lipid Res., October 1, 2004; 45(10): 1868 - 1875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Lewis and E. J Brunner Methodological problems in genetic association studies of longevity--the apolipoprotein E gene as an example Int. J. Epidemiol., October 1, 2004; 33(5): 962 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Moreno, F. Perez-Jimenez, C. Marin, P. Gomez, P. Perez-Martinez, R. Moreno, C. Bellido, F. Fuentes, and J. Lopez-Miranda The Effect of Dietary Fat on LDL Size Is Influenced by Apolipoprotein E Genotype in Healthy Subjects J. Nutr., October 1, 2004; 134(10): 2517 - 2522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Keavney, A. Palmer, S. Parish, S. Clark, L. Youngman, J. Danesh, C. McKenzie, M. Delepine, M. Lathrop, R. Peto, et al. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk Int. J. Epidemiol., October 1, 2004; 33(5): 1002 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Austin, C. M. Hutter, R. L. Zimmern, and S. E. Humphries Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association Review Am. J. Epidemiol., September 1, 2004; 160(5): 421 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. MacKensen, M. Swaminathan, L. K. Ti, H. P. Grocott, B. G. Phillips-Bute, J. P. Mathew, M. F. Newman, C. A. Milano, and M. Stafford-Smith Preliminary report on the interaction of apolipoprotein E polymorphism with aortic atherosclerosis and acute nephropathy after CABG Ann. Thorac. Surg., August 1, 2004; 78(2): 520 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Song, M. J. Stampfer, and S. Liu Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease Ann Intern Med, July 20, 2004; 141(2): 137 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saito, M. Eto, H. Nitta, Y. Kanda, M. Shigeto, K. Nakayama, K. Tawaramoto, F. Kawasaki, S. Kamei, K. Kohara, et al. Effect of Apolipoprotein E4 Allele on Plasma LDL Cholesterol Response to Diet Therapy in Type 2 Diabetic Patients Diabetes Care, June 1, 2004; 27(6): 1276 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.J. C. Slooter, M. Cruts, A. Hofman, P. J. Koudstaal, D. van der Kuip, M.A. J. de Ridder, J.C. M. Witteman, M.M. B. Breteler, C. Van Broeckhoven, and C. M. van Duijn The impact of APOE on myocardial infarction, stroke, and dementia: The Rotterdam Study Neurology, April 13, 2004; 62(7): 1196 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Humphries, P. M. Ridker, and P. J. Talmud Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation? Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 628 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Novaro, R. Sachar, G. L. Pearce, D. L. Sprecher, and B. P. Griffin Association Between Apolipoprotein E Alleles and Calcific Valvular Heart Disease Circulation, October 14, 2003; 108(15): 1804 - 1808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Cooper Gene-Environment Interactions and the Etiology of Common Complex Disease Ann Intern Med, September 2, 2003; 139(5_Part_2): 437 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Infante-Rivard, E Levy, G-E Rivard, M Guiguet, and J-C Feoli-Fonseca Small babies receive the cardiovascular protective apolipoprotein {varepsilon}2 allele less frequently than expected J. Med. Genet., August 1, 2003; 40(8): 626 - 629. [Full Text]
|
|
|
|
 |
|
 A. F. Jorm, M. Prior, A. Sanson, D. Smart, Y. Zhang, and S. Easteal Apolipoprotein E Genotype and Temperament: A Longitudinal Study From Infancy to the Late Teens Psychosom Med, July 1, 2003; 65(4): 662 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Chen, S. E. Reis, C. Kammerer, W. Y. Craig, S. E. LaPierre, E. L. Zimmer, D. M. McNamara, D. F. Pauly, B. Sharaf, R. Holubkov, et al. Genetic Variation in Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 (LOX1) Gene and the Risk of Coronary Artery Disease Circulation, July 1, 2003; 107(25): 3146 - 3151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. S. Tan, S. Seshadri, A. Beiser, P. W. F. Wilson, D. P. Kiel, M. Tocco, R. B. D'Agostino, and P. A. Wolf Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease: The Framingham Study Arch Intern Med, May 12, 2003; 163(9): 1053 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, J. F. Carlquist, B. D. Home, and J. B. Muhlestein Cardiovascular Pharmacogenomics: Current Status, Future Prospects Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 71 - 83. [Abstract] [PDF]
|
|
|
|
|
|
G. Davey Smith and S. Ebrahim 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol., February 1, 2003; 32(1): 1 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kolovou, D. Daskalova, and D. P. Mikhailidis Apolipoprotein E Polymorphism and Atherosclerosis Angiology, January 1, 2003; 54(1): 59 - 71. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Jacobsen, J. Bentzen, M. Meldgaard, M. H. Jakobsen, M. Fenger, S. Kauppinen, and J. Skouv LNA-enhanced detection of single nucleotide polymorphisms in the apolipoprotein E Nucleic Acids Res., October 1, 2002; 30(19): e100 - e100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kivipelto, E.-L. Helkala, M. P. Laakso, T. Hanninen, M. Hallikainen, K. Alhainen, S. Iivonen, A. Mannermaa, J. Tuomilehto, A. Nissinen, et al. Apolipoprotein E {epsilon}4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease Ann Intern Med, August 6, 2002; 137(3): 149 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Keavney Genetic epidemiological studies of coronary heart disease Int. J. Epidemiol., August 1, 2002; 31(4): 730 - 736. [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Fillenbaum, D. G. Blazer, B. M. Burchett, A. M. Saunders, and D. H. Taylor Jr. Apolipoprotein E {varepsilon}4 and Risk of Mortality in African American and White Older Community Residents Gerontologist, June 1, 2002; 42(3): 381 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Djousse, R. H. Myers, M. A. Province, S. C. Hunt, J. H. Eckfeldt, G. Evans, J. M. Peacock, and R. C. Ellison Influence of Apolipoprotein E, Smoking, and Alcohol Intake on Carotid Atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study Stroke, May 1, 2002; 33(5): 1357 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Austin Ethical Issues in Human Genome Epidemiology: A Case Study Based on The Japanese American Family Study in Seattle, Washington Am. J. Epidemiol., April 1, 2002; 155(7): 585 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Dansky, P. Shu, M. Donavan, J. Montagno, D. L. Nagle, J. S. Smutko, N. Roy, S. Whiteing, J. Barrios, T. J. McBride, et al. A Phenotype-Sensitizing Apoe-Deficient Genetic Background Reveals Novel Atherosclerosis Predisposition Loci in the Mouse Genetics, April 1, 2002; 160(4): 1599 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. R. P. Agema, J. W. Jukema, S. N. Pimstone, and J. J. P. Kastelein Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy Eur. Heart J., November 2, 2001; 22(22): 2058 - 2074. [PDF]
|
|
|
|
|
|
A.J.C. Slooter, M. L. Bots, L. M. Havekes, A. I. del Sol, M. Cruts, D. E. Grobbee, A. Hofman, C. Van Broeckhoven, J.C.M. Witteman, and C. M. van Duijn Apolipoprotein E and Carotid Artery Atherosclerosis: The Rotterdam Study Stroke, September 1, 2001; 32(9): 1947 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Berglund The APOE gene and diets--food (and drink) for thought Am. J. Clinical Nutrition, April 1, 2001; 73(4): 669 - 670. [Full Text] [PDF]
|
|
|
|
|
|
A. T Erkkila, E. S Sarkkinen, V. Lindi, S. Lehto, M. Laakso, and M. I. Uusitupa APOE polymorphism and the hypertriglyceridemic effect of dietary sucrose Am. J. Clinical Nutrition, April 1, 2001; 73(4): 746 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Steed, R. Kong, J. Stygall, J. Acharya, M. Bolla, M. J.G. Harrison, S. E. Humphries, and S. P. Newman The role of apolipoprotein E in cognitive decline after cardiac operation Ann. Thorac. Surg., March 1, 2001; 71(3): 823 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Frikke-Schmidt, B.G. Nordestgaard, D. Thudium, M.-L. Moes Gronholdt, and A. Tybjarg-Hansen APOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease Neurology, January 23, 2001; 56(2): 194 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.o. G. Nordestgaard, R. Frikke-Schmidt, and A. Tybjaerg-Hansen Mild hypercholesterolemia and premature heart disease: Reply J. Am. Coll. Cardiol., January 1, 2001; 37(1): 331 - 332. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hadjadj, Y. Gallois, G. Simard, B. Bouhanick, P. Passa, A. Grimaldi, P. Drouin, J. Tichet, and M. Marre Lack of relationship in long-term type 1 diabetic patients between diabetic nephropathy and polymorphisms in apolipoprotein {varepsilon}, lipoprotein lipase and cholesteryl ester transfer protein Nephrol. Dial. Transplant., December 1, 2000; 15(12): 1971 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Batalla, R. Alvarez, J. R. Reguero, S. Hevia, G. Iglesias-Cubero, V. Alvarez, A. Cortina, P. Gonzalez, M. M. Celada, A. Medina, et al. Synergistic Effect between Apolipoprotein E and Angiotensinogen Gene Polymorphisms in the Risk for Early Myocardial Infarction Clin. Chem., December 1, 2000; 46(12): 1910 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne, J. A. Herd, E. A. Stein, L. L. Ferlic, J. K. Dunn, A. M. Gotto Jr., and A. J. Marian Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1572 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. McCarron, K. W. Muir, J. A. R. Nicoll, J. Stewart, Y. Currie, K. Brown, and I. Bone Prospective Study of Apolipoprotein E Genotype and Functional Outcome Following Ischemic Stroke Arch Neurol, October 1, 2000; 57(10): 1480 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Isasi, S. Shea, R. J. Deckelbaum, S. C. Couch, T. J. Starc, J. D. Otvos, and L. Berglund Apolipoprotein epsilon 2 Allele Is Associated With an Anti-atherogenic Lipoprotein Profile in Children: The Columbia University BioMarkers Study Pediatrics, September 1, 2000; 106(3): 568 - 575. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. Waterworth, J. A. Hubacek, J. Pitha, J. Kovar, R. Poledne, S. E. Humphries, and P. J. Talmud Plasma levels of remnant particles are determined in part by variation in the APOC3 gene insulin response element and the APOCI;-APOE cluster J. Lipid Res., July 1, 2000; 41(7): 1103 - 1109. [Abstract] [Full Text]
|
|
|
|
|
|
M. Nauck, M. M. Hoffmann, H. Wieland, and W. Marz Evaluation of the Apo E Genotyping Kit on the LightCycler, Clin. Chem., May 1, 2000; 46(5): 722 - 724. [Full Text] [PDF]
|
|
|
|
|
|
R. Frikke-Schmidt, A. Tybjaerg-Hansen, R. Steffensen, G. Jensen, and B.o. G. Nordestgaard Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: The Copenhagen City Heart Study J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1192 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. U. Gerdes, C. Gerdes, K. Kervinen, M. Savolainen, I. C. Klausen, P. S. Hansen, Y. A. Kesaniemi, and O. Fargeman The Apolipoprotein {epsilon}4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial Infarction : A Substudy of the Scandinavian Simvastatin Survival Study Circulation, March 28, 2000; 101(12): 1366 - 1371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Dart and B. Cooper Independent Effects of Apo E Phenotype and Plasma Triglyceride on Lipoprotein Particle Sizes in the Fasting and Postprandial States Arterioscler Thromb Vasc Biol, October 1, 1999; 19(10): 2465 - 2473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. McCarron, D. Delong, and M. J. Alberts APOE genotype as a risk factor for ischemic cerebrovascular disease: A meta-analysis Neurology, October 1, 1999; 53(6): 1308 - 1308. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ilveskoski, M. Perola, T. Lehtimaki, P. Laippala, V. Savolainen, J. Pajarinen, A. Penttila, K. H. Lalu, A. Mannikko, K. K. Liesto, et al. Age-Dependent Association of Apolipoprotein E Genotype With Coronary and Aortic Atherosclerosis in Middle-Aged Men : An Autopsy Study Circulation, August 10, 1999; 100(6): 608 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Romas, M.-X. Tang, L. Berglund, and R. Mayeux APOE genotype, plasma lipids, lipoproteins, and AD in community elderly Neurology, August 1, 1999; 53(3): 517 - 517. [Abstract] [Full Text]
|
|
|
|
|
|
C. Merchant, M.-X. Tang, S. Albert, J. Manly, Y. Stern, and R. Mayeux The influence of smoking on the risk of Alzheimer's disease Neurology, April 1, 1999; 52(7): 1408 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Inbal, D. Freimark, B. Modan, A. Chetrit, S. Matetzky, N. Rosenberg, R. Dardik, Z. Baron, and U. Seligsohn Synergistic Effects of Prothrombotic Polymorphisms and Atherogenic Factors on the Risk of Myocardial Infarction in Young Males Blood, April 1, 1999; 93(7): 2186 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. S. Mamotte, M. Sturm, J. I. Foo, F. M. van Bockxmeer, and R. R. Taylor Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E553 - E557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Margaglione, D. Seripa, C. Gravina, E. Grandone, G. Vecchione, G. Cappucci, G. Merla, S. Papa, A. Postiglione, G. Di Minno, et al. Prevalence of Apolipoprotein E Alleles in Healthy Subjects and Survivors of Ischemic Stroke : An Italian Case-Control Study Stroke, February 1, 1998; 29(2): 399 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Zaman, S. Ikemoto, N. Yoshiike, C. Date, T. Yokoyama, and H. Tanaka Association of Apolipoprotein Genetic Polymorphisms With Plasma Cholesterol in a Japanese Rural Population : The Shibata Study Arterioscler Thromb Vasc Biol, December 1, 1997; 17(12): 3495 - 3504. [Abstract] [Full Text]
|
|
|
|
|
|
A. Pablos-Mendez, R. Mayeux, C. Ngai, S. Shea, and L. Berglund Association of Apo E Polymorphism With Plasma Lipid Levels in a Multiethnic Elderly Population Arterioscler Thromb Vasc Biol, December 1, 1997; 17(12): 3534 - 3541. [Abstract] [Full Text]
|
|
|
|
|
|
A. Zivelin, N. Rosenberg, H. Peretz, Y. Amit, N. Kornbrot, and U. Seligsohn Improved Method for Genotyping Apolipoprotein E Polymorphisms by a PCR-Based Assay Simultaneously Utilizing Two Distinct Restriction Enzymes Clin. Chem., September 1, 1997; 43(9): 1657 - 1659. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||